Financial Performance - Consolidated INNOVATE reported Q1 2025 revenue of $274.2 million, a decrease of $41.0 million or 13% compared to $315.2 million in Q1 2024[17, 22] - Net loss attributable to INNOVATE Corp was $24.5 million in Q1 2025[18, 22, 41] - Adjusted EBITDA decreased by $5.6 million to $7.2 million in Q1 2025, compared to $12.8 million in Q1 2024[18, 22] Segment Highlights - Infrastructure (DBMG) - Infrastructure segment revenue decreased to $264.9 million in Q1 2025 from $307.9 million in Q1 2024, a 14% decrease[17, 25, 27] - Infrastructure segment Adjusted EBITDA decreased to $16.7 million in Q1 2025 from $18.3 million in Q1 2024[18, 25, 27] - DBMG's adjusted backlog ended the first quarter with $1.4 billion, including over $500 million in new awards[12, 15, 27] Segment Highlights - Life Sciences (R2 Technologies) - Life Sciences segment revenue increased to $3.1 million in Q1 2025 from $1.0 million in Q1 2024, a 210% increase[17, 22] - R2 Technologies experienced gross system unit sales growth of 109% over the prior year quarter in North America and 163% worldwide[32] Segment Highlights - Spectrum - Spectrum segment revenue was $6.2 million in Q1 2025, compared to $6.3 million in Q1 2024[17, 33] - Spectrum segment Adjusted EBITDA was $1.4 million in Q1 2025, compared to $1.6 million in Q1 2024[12, 18, 33] Debt - Total principal outstanding debt was $672.0 million as of March 2025[36]

Core Insights - INNOVATE Corp. reported a consolidated revenue of $274.2 million for Q1 2025, a decrease of 13.0% compared to $315.2 million in Q1 2024, primarily driven by the Infrastructure segment [2][8] - The company experienced a net loss attributable to common stockholders of $24.8 million, or $1.89 per share, compared to a net loss of $17.7 million, or $2.21 per share, in the prior year [2][12] - Adjusted EBITDA for Q1 2025 was $7.2 million, down 43.8% from $12.8 million in Q1 2024, reflecting challenges in both the Life Sciences and Infrastructure segments [2][14] Infrastructure Segment - DBM Global reported Q1 2025 revenue of $264.9 million, a decrease of 14.0% from $307.9 million in the prior year [4][9] - The adjusted backlog for DBM Global increased to $1.4 billion, up from $1.0 billion as of December 31, 2024, indicating strong project acquisition [5][4] - Gross margin improved to 15.6%, an increase of approximately 110 basis points year-over-year, while adjusted EBITDA margin rose to 6.3%, an increase of approximately 40 basis points [4][5] Life Sciences Segment - MediBeacon's Transdermal GFR System received FDA approval, enhancing growth prospects in the Life Sciences segment [3][10] - R2 Technologies reported a revenue of $3.1 million, a 210% increase compared to $1.0 million in the prior year, driven by increased unit sales [10][3] - The Life Sciences segment's adjusted EBITDA was negative at $(8.7) million, a decrease from $(4.2) million in the prior year, primarily due to higher equity method losses from MediBeacon [14][12] Spectrum Segment - The Spectrum segment reported revenue of $6.2 million, slightly down from $6.3 million in the prior year [10][9] - The company is exploring commercial opportunities in datacasting, with expectations to generate revenue by the end of 2025 [10][3] Financial Performance - Total adjusted EBITDA for Q1 2025 was $7.2 million, down from $12.8 million in Q1 2024, primarily due to declines in the Life Sciences and Infrastructure segments [14][12] - The company had cash and cash equivalents of $33.3 million as of March 31, 2025, down from $48.8 million at the end of 2024 [14][30] - The total liabilities increased to $1,036.9 million as of March 31, 2025, compared to $1,034.8 million at the end of 2024 [30][31]

Core Insights - INNOVATE Corp. reported a consolidated revenue of $236.6 million for Q4 2024, a decrease of 34.5% compared to $361.0 million in Q4 2023, primarily driven by the Infrastructure segment [2][8] - The company experienced a net loss attributable to common stockholders of $16.9 million, or $1.29 per share, compared to a loss of $9.6 million, or $1.22 per share, in the prior year quarter [2][11] - The Infrastructure segment's revenue decreased to $225.7 million, down 36.2% from $353.8 million in the prior year quarter, while the Life Sciences and Spectrum segments showed growth [4][11] Financial Summary - Total Adjusted EBITDA for Q4 2024 was $15.0 million, down from $21.5 million in Q4 2023, reflecting challenges in the Infrastructure segment [14][15] - The company reduced its total debt by $54.5 million year-over-year, indicating improved financial health [3] Segment Performance Infrastructure - DBM Global's revenue for Q4 2024 was $225.7 million, a decrease of 36.2% year-over-year, with an adjusted backlog of $1.1 billion as of December 31, 2024 [4][5] - Gross margin improved to 18.2%, an increase of approximately 180 basis points year-over-year, despite a decrease in Adjusted EBITDA margin [4] Life Sciences - MediBeacon's TGFR system received FDA approval in January 2025, marking a significant milestone for the Life Sciences segment [10] - R2 Technologies reported a 113% increase in worldwide system unit sales in Q4 2024 compared to Q4 2023 [10] Spectrum - Broadcasting segment achieved double-digit revenue growth in Q4 2024, with revenue of $6.8 million compared to $5.7 million in the prior year quarter [10][11] Operational Highlights - The company announced collaborations in the Life Sciences segment with Woodhouse Spas and leading skincare brands, indicating strong market momentum [3] - Successful new network launches in the Spectrum segment contributed to revenue growth, despite some terminations of smaller networks [10]